| |
Explore dynamic forces reshaping how therapies reach patients and gain actionable insights on market access and patient support from industry experts in this podcast series from Asembia's AXS25 Summit. Listen now. .png)
|
|
Today’s Big NewsMay 8, 2025 |
|
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. |
|
| By Nick Paul Taylor Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process. The two terminations, coupled to the removal of a third asset, halved the number of cancer candidates in Takeda’s phase 1 and 2 pipeline. |
|
|
|
By James Waldron California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies. |
By Darren Incorvaia Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. |
Sponsored by 89bio How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for. |
|
No matter where you are in your biologics development journey, you need reliable, high-quality analytical data to move forward with confidence. Our full-spectrum analytical testing services are designed to meet your evolving needs, from early to late stage clinical and beyond. 
|
|
By James Waldron Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its clinical-stage candidate for a genetic lung and liver disease. |
By Ben Adams RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after discontinuing its lead drug program and just over a year after a similar cost-cutting drive. |
By Ben Adams Another Big Pharma is opening up its wallet to pour billions into its U.S. operations. |
By Nick Paul Taylor GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary endpoint. |
By Nick Paul Taylor NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial. |
By Gabrielle Masson,Darren Incorvaia The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Nick Paul Taylor CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ahead with dose escalation. |
By Darren Incorvaia Charles River Laboratories is initiating a strategic review and shaking up its board amid a chaotic biopharma ecosystem and declining revenues. |
By Fraiser Kansteiner With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," hear how the founders of ElevAAte are turning shared East Asian American experiences into collective power for the next generation of biopharma leaders. |
|
|---|
|
|
|
Thursday, May 15, 2025 | 12pm ET / 9am PT Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| |
|
